Sign In
Buy GMAB
$25.94
+0.330 (+1.29%)
At Close: Jun 23, 2026
CureVac Founder Ingmar Hoerr to Replace CEO Dan Menichella
07:06am, Friday, 13'th Mar 2020
German biotech CureVac, a developer of messenger RNA-based drugs, said company founder Ingmar Hoerr would take over for CEO Dan Menichella. Menichella
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
12:46pm, Friday, 21'st Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose B
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
12:06pm, Thursday, 20'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia
Andreas Halvorsen Trims Adaptive Biotechnologies Stake
04:27pm, Monday, 03'rd Feb 2020
The immune-driven biotech company went public last June Continue reading...
Retrophin (NASDAQ:RTRX) and Genmab A/S (NASDAQ:GMAB) Head-To-Head Comparison
08:25am, Monday, 27'th Jan 2020
Retrophin (NASDAQ:RTRX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, ea
Retrophin (NASDAQ:RTRX) and Genmab A/S (NASDAQ:GMAB) Financial Review
07:31am, Saturday, 25'th Jan 2020
Retrophin (NASDAQ:RTRX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recomm
